Multiple Skleroz ve Aşılar

Levin SN, Kaplan TB. Infectious Complications of Novel Multiple Sclerosis Therapies. Curr Infect Dis Rep. Şubat 2017;19(2):7.

Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol. Mart 2012;8(3):143-51.

Amin M, Hersh CM. Updates and Advances in Multiple Sclerosis Neurotherapeutics. Neurodegener Dis Manag. Şubat 2023;13(1):47-70.

Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. Mart 2021;20(3):179-99.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, vd. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 19 Ocak 2017;376(3):221-34.

Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, vd. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology [Internet]. 06 Ekim 2020 [a.yer 17 Aralık 2024];95(14). Erişim adresi: https://www.neurology.org/doi/10.1212/WNL.0000000000010380

Jaber A, Patel M, Sylvester A, Yarussi M, Kalina JT, Mendoza JP, vd. COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy. Neurol Ther. Nisan 2023;12(2):687-700.

Otero-Romero S, Lebrun-Frénay C, Reyes S, Amato MP, Campins M, Farez M, vd. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. Temmuz 2023;29(8):904-25.

Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, vd. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis & Rheumatism. Ocak 2010;62(1):64-74.

Kornek B, Leutmezer F, Rommer PS, Koblischke M, Schneider L, Haslacher H, vd. B Cell Depletion and SARS‐COV ‐2 Vaccine Responses in Neuroimmunologic Patients. Annals of Neurology. Mart 2022;91(3):342-52.

Achtnichts L, Jakopp B, Oberle M, Nedeltchev K, Fux CA, Sellner J, vd. Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis. Vaccines. 11 Aralık 2021;9(12):1470.

Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, vd. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. Kasım 2021;27(11):1990-2001.

Coles AJ. Alemtuzumab Therapy for Multiple Sclerosis. Neurotherapeutics. Ocak 2013;10(1):29-33.

McCarthy CL, Tuohy O, Compston DAS, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 03 Eylül 2013;81(10):872-6.

Carlson AK, Amin M, Cohen JA. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. Drugs. Mart 2024;84(3):285-304.

Faissner S, Heitmann N, Plaza-Sirvent C, Trendelenburg P, Ceylan U, Motte J, vd. Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination. Front Immunol. 31 Ağustos 2022;13:980526.

Krajnc N, Bsteh G, Berger T, Mares J, Hartung HP. Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics. Nisan 2022;19(3):753-73.

Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, vd. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 06 Ağustos 2013;81(6):552-8.

Van Sleen Y, Van Der Geest KSM, Huckriede ALW, Van Baarle D, Brouwer E. Effect of DMARDs on the immunogenicity of vaccines. Nat Rev Rheumatol. Eylül 2023;19(9):560-75.

Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, vd. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care & Research. Mart 2023;75(3):449-64.

Schmierer K, Wiendl H, Oreja-Guevara C, Centonze D, Chudecka A, Roy S, vd. Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. Mult Scler. Kasım 2022;28(13):2151-3.

Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger EC, vd. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies. CNS Neurosci Ther. Şubat 2019;25(2):245-54.

Vågberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurological Research. Eylül 2012;34(7):730-3.

Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences. Haziran 2014;341(1-2):22-7.

Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, vd. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. eBioMedicine. Ekim 2021;72:103581.

Bsteh G, Hegen H, Traxler G, Krajnc N, Leutmezer F, Di Pauli F, vd. Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. Euro J of Neurology. Mayıs 2022;29(5):1538-44.

Paybast S, Sahraian MA, Nahayati MA, Habibi MA, Shahmohammadi S, Navardi S. Investigation of the safety of live attenuated varicella-zoster virus vaccination in patients with relapse-remitting multiple sclerosis treated with natalizumab: A case series and review of the literature. Multiple Sclerosis and Related Disorders. Eylül 2023;77:104793.

Alping P, Askling J, Burman J, Fink K, Fogdell‐Hahn A, Gunnarsson M, vd. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology. Mayıs 2020;87(5):688-99.

S. G, S. L, C. Z, A. N, M. F, L. M. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. J Neurol. Ocak 2022;269(1):39-43.

Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, Gasser O, vd. Antigen‐specific adaptive immune responses in fingolimod‐treated multiple sclerosis patients. Annals of Neurology. Şubat 2011;69(2):408-13.

Boulton C, Meiser K, David OJ, Schmouder R. Pharmacodynamic Effects of Steady‐State Fingolimod on Antibody Response in Healthy Volunteers: A 4‐Week, Randomized, Placebo‐Controlled, Parallel‐Group, Multiple‐Dose Study. The Journal of Clinical Pharma. Aralık 2012;52(12):1879-90.

Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, Lampe J, vd. Biological response genes after single dose administration of interferon β-1b to healthy male volunteers. Journal of Neuroimmunology. Ağustos 2008;199(1-2):115-25.

Olberg HK, Eide GE, Cox RJ, Jul‐Larsen Å, Lartey SL, Vedeler CA, vd. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Euro J of Neurology. Mart 2018;25(3):527-34.

Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler. Temmuz 2014;20(8):1074-80.

Schwid SR, Decker MD, Lopez-Bresnahan M. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 27 Aralık 2005;65(12):1964-6.

Mehling M, Fritz S, Hafner P, Eichin D, Yonekawa T, Klimkait T, vd. Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy. Oreja-Guevara C, editör. PLoS ONE. 05 Kasım 2013;8(11):e78532.

Von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, vd. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. Ocak 2018;5(1):e409.

Solmaz I, Anlar B. Immunization in multiple sclerosis and other childhood immune-mediated disorders of the central nervous system: A review of the literature. European Journal of Paediatric Neurology. Temmuz 2021;33:125-34.

Golli T, Kastrin A, Pokorn M, Rener-Primec Z. Immunosuppression and immunization: Vaccination in pediatric patients with neuromuscular diseases treated with steroids or immune-modulating drugs. European Journal of Paediatric Neurology. Kasım 2021;35:158-64.

John Looney R, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Practice & Research Clinical Haematology. Mart 2006;19(1):3-25.

Cardenas‐Brown C, Lucas RD, Buttery J, Britton PN, Wood N, Singh‐Grewal D, vd. Live vaccines following intravenous immunoglobulin for Kawasaki disease: Are we vaccinating appropriately? J Paediatrics Child Health. Kasım 2023;59(11):1217-22.